Tg Therapeutics (TGTX) Operating Expenses (2011 - 2026)

Tg Therapeutics' Operating Expenses history runs 16 years deep, the most recent figure standing at $170.1 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 51.58% year-over-year to $170.1 million; the TTM figure through Mar 2026 stood at $550.9 million (up 68.68% YoY), while the FY2025 annual figure was $493.0 million, up 71.72% from the prior year.
• Operating Expenses was $170.1 million for Q1 2026 at Tg Therapeutics, up from $142.1 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $170.1 million in Q1 2026 to a low of $35.1 million in Q3 2022.
• Historically, Operating Expenses has averaged $81.4 million across 5 years, with a median of $71.4 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Operating Expenses sank 59.78% in 2022, then surged 85.24% in 2025.
• A 5-year view of Operating Expenses shows it stood at $77.6 million in 2022, then slipped by 27.27% to $56.5 million in 2023, then surged by 38.58% to $78.2 million in 2024, then jumped by 81.6% to $142.1 million in 2025, then grew by 19.74% to $170.1 million in 2026.
• The last three Operating Expenses figures came in at $170.1 million (Q1 2026), $142.1 million (Q4 2025), and $132.3 million (Q3 2025), per Business Quant data.